Brief: Symbiotec Pharmalab Receives U.S. FDA Eir For Pithampur Facility With Vai Status
29/09/2026 06:31
BRIEF-Symbiotec Pharmalab Receives U.S. FDA Eir For Pithampur Facility With Vai Status Sept 29 (Reuters) - Symbiotec Pharmalab Limited SYMI.NS:
RECEIVES USFDA EIR FOR PITHAMPUR FACILITY WITH VAI STATUS
Further company coverage: SYMI.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Symbiotec Pharmalab
See all newsIndia's Symbiotec Pharmalab rises on US drug distribution deal
Brief: Symbiotec Pharmalab Unit Enters Into Strategic Commercialization Agreement
Brief: Symbiotec Pharmalab Receives U.S. FDA Eir For Pithampur Facility With Vai Status
India's Symbiotec Pharmalab declines after Q1 profit fall
India's Symbiotec Pharmalab rises after muted debut, valued at $779 million